StockNews.AI
ZLAB
StockNews.AI
120 days

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

1. Zai Lab's sNDA for repotrectinib accepted by China's NMPA. 2. Targeted treatment for solid tumors with NTRK gene fusion shows promise.

2m saved
Insight
Article

FAQ

Why Bullish?

Acceptance of the sNDA enhances ZLAB's market positioning similar to previous FDA approvals for oncology drugs, positively affecting stock valuation.

How important is it?

The sNDA acceptance can lead to increased revenue, making it a significant catalyst for ZLAB's stock price.

Why Long Term?

NMPA approval could lead to increased sales and market share over time, similar to other oncology products by ZLAB that gained traction post-approval.

Related Companies

NTRKEXELMRNA
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The application is intended for patients whose disease is locally advanced or metastatic, or where surgical resection is likely to.

Related News